← Back to Patent Explorer
US6358539B1 Expired / Lapsed US ⏱️ 0.0 years remaining

Pharmaceutical compositions for reducing the appearance of cellulite

Assignee: Unilever NV
•
Filing: 2000-08-18
•
Granted: 2002-03-19
•
Expires: 2020-08-18
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Compositions and methods for reducing or eliminating the appearance of cellulite. The method involves administering to a patient in need of treatment therapeutically effective amounts of a sugar compound that is converted to a glycosaminoglycan in the patient in an amount sufficient to thicken the skin, a primary antioxidant component in an amount sufficient to substantially inhibit the formation of collagenase and elastase, at least one amino acid component in an amount sufficient to assist in the thickening of the skin, and at least one transition metal component in an amount effective to bind collagen and elastic fibers and thicken skin so as to reduce or eliminate the appearance of cellulite. A preferred method of treatment further includes administering the components above in conjunction with a vascular dilator to improve blood supply to the skin and/or a fat burner to reduce absorption or digestion of fat in the digestive tract or to prevent the production of fat. The compositions and methods may optionally include chromium picolinate to facilitate entry of sugar into cells to improve fat metabolism. In one embodiment, these methods encompass administering the amounts as a pharmaceutical composition.

Inventors

  • 👤 Howard Murad

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 15:33
CPC Classifications
A; A61; A61K; A61K8/00; A61K8/18; A61K8/30; A61K8/60; A61K8/19; A61K8/27; A61K8/40; A61K8/44; A61K8/67; A61K8/676; A61P; A61P17/00; A61P43/00; A61Q; A61Q19/00; A61Q19/06

Claims Analysis

Total Claims: 17
Claim 1
Independent Claim 147 words
A pharmaceutical composition for reducing or eliminating the appearance of cellulite in a patient comprising: a sugar compound that is converted to a glycosaminoglycan in the patient in an amount sufficient to thicken the skin; a primary antioxidant component in an amount sufficient to substantially inhibit the activity of collagenase and elastase; at least one amino acid component in an amount sufficient to assist in the thickening of the skin; at least one transition metal component in an amount effective to bind collagen and elastic fibers and thicken the skin; at least one of either a fat burner to reduce absorption of fat in the digestive tract or prevent the production of fat, or a vascular dilator to improve blood supply to the skin; and chromium picolinate in an amount sufficient to facilitate entry of sugar into the cells to improve metabolism of fats by the body.
Claim 2
Dependent Claim 147 words
A pharmaceutical composition for reducing or eliminating the appearance of cellulite in a patient comprising: a sugar compound that is converted to a glycosaminoglycan in the patient in an amount sufficient to thicken the skin; a primary antioxidant component in an amount sufficient to substantially inhibit the activity of collagenase and elastase; at least one amino acid component in an amount sufficient to assist in the thickening of the skin; at least one transition metal component in an amount effective to bind collagen and elastic fibers and thicken the skin; at least one of either a fat burner to reduce absorption of fat in the digestive tract or prevent the production of fat, or a vascular dilator to improve blood supply to the skin; and chromium picolinate in an amount sufficient to facilitate entry of sugar into the cells to improve metabolism of fats by the body.
Claim 3
Dependent Claim 11 words
The composition of claim 1 wherein a fat burner is present.
Claim 4
Dependent Claim 11 words
The composition of claim 1 wherein a vascular dilator is present.
Claim 5
Dependent Claim 84 words
The composition of claim 1 , wherein the sugar compound is present in an amount of from about 5 to 50 weight percent of the composition, the primary antioxidant component is present in an amount of about 5 to 50 weight percent of the composition, the amino acid component is present in an amount of about 8 to 60 weight percent of the composition, and the transition metal component is present in an amount of about 0.5 to 15 weight percent of the composition.
Claim 6
Dependent Claim 20 words
The composition of claim 1 , wherein the sugar compound is N-acetylglucosamine, or a pharmaceutically acceptable salt or ester thereof.
Claim 7
Dependent Claim 32 words
The composition of claim 5 , wherein the N-acetylglucosamine, or a pharmaceutically acceptable salt or ester thereof, is present in an amount of about 5 to 30 weight percent of the composition.
Claim 8
Dependent Claim 14 words
The composition of claim 1 , wherein the anti-oxidant is a vitamin C source.
Claim 9
Dependent Claim 26 words
The composition of claim 7 , wherein the vitamin C source is present in an amount of about 5 to 50 weight percent of the composition.
Claim 10
Dependent Claim 21 words
The composition of claim 1 , wherein the amino acids are selected from lysine, proline, cysteins, glycine, methionine, or mixtures thereof.
Claim 11
Dependent Claim 26 words
The composition of claim 9 , wherein the amino acids are each present in an amount of about 2 to 25 weight percent of the composition.
Claim 12
Dependent Claim 19 words
The composition of claim 1 , wherein the transition metal is one or more of zinc, manganese, or copper.
Claim 13
Dependent Claim 65 words
The composition of claim 11 , wherein the zinc, if present, is present in an amount of about 1 to 10 weight percent of the composition; the manganese, if present, is present in an amount of about 1 to 10 weight percent of the composition; and the copper, if present, is present in an amount of about 0.1 to 5 weight percent of the composition.
Claim 14
Dependent Claim 12 words
The composition of claim 1 , further comprising a proanthanol or proanthocyanidin.
Claim 15
Dependent Claim 25 words
The composition of claim 13 , wherein the proanthanol or proanthocyanidin is present in an amount of 0.5 to 5 weight percent of the composition.
Claim 16
Dependent Claim 25 words
The composition of claim 3 , wherein the vascular dilator is one or more of an extract of ginko biloba, a ginsing extract, or phenylalanine.
Claim 17
Dependent Claim 16 words
The composition of claim 2 , wherein the fat burner is hydroxy acetic acid or chitin.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2005-03-18 2005-09-17 2006-03-19 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2009-03-18 2009-09-17 2010-03-19 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2013-03-18 2013-09-17 2014-03-19 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag